<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01341353</url>
  </required_header>
  <id_info>
    <org_study_id>CAPA001</org_study_id>
    <nct_id>NCT01341353</nct_id>
  </id_info>
  <brief_title>Catheter Ablation Versus Antiarrythmic Drugs for Atrial Fibrillation in China</brief_title>
  <official_title>Atrial Fibrillation Therapy: A Multi-Center Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wuhan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The mainstay of treatment for atrial fibrillation remains pharmacological;however,catheter
      ablation has increasingly been used over the last decades. The relative merits of each
      strategy have not been extensively studied. Our study was designed to determine if catheter
      ablation is a feasible option as first-line therapy for treating patients with symptomatic
      AF.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with all-cause death</measure>
    <time_frame>3 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with all-cause death</measure>
    <time_frame>12 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with all-cause death</measure>
    <time_frame>24 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with all-cause death</measure>
    <time_frame>36 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>severe blooding complications</measure>
    <time_frame>3 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>severe blooding complications</measure>
    <time_frame>12 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>severe blooding complications</measure>
    <time_frame>24 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>severe blooding complications</measure>
    <time_frame>36 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>cardio-cerebrovascular complications</measure>
    <time_frame>3 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>cardio-cerebrovascular complications</measure>
    <time_frame>12 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>cardio-cerebrovascular complications</measure>
    <time_frame>24 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>cardio-cerebrovascular complications</measure>
    <time_frame>36 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with cardiovascular death events</measure>
    <time_frame>3 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with cardiovascular death events</measure>
    <time_frame>12 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with cardiovascular death events</measure>
    <time_frame>24 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with cardiovascular death events</measure>
    <time_frame>36 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>recurrence of atrial arrhythmias (AF, AFL, AT)</measure>
    <time_frame>3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>recurrence of atrial arrhythmias (AF, AFL, AT)</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>recurrence of atrial arrhythmias (AF, AFL, AT)</measure>
    <time_frame>24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>recurrence of atrial arrhythmias (AF, AFL, AT)</measure>
    <time_frame>36 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>resource utilization and costs</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>resource utilization and costs</measure>
    <time_frame>24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>resource utilization and costs</measure>
    <time_frame>36 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1800</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Antiarrythmic Drugs</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>catheter ablation</intervention_name>
    <description>circumferential pulmonary vein isolation complex fractionated atrial electrograms ablation circumferential pulmonary vein isolation combined left atrial roof ablation circumferential pulmonary vein isolation combined left atrial isthmus ablation circumferential pulmonary vein isolation combined left atrial roof and isthmus ablation circumferential pulmonary vein isolation combined complex fractionated atrial electrograms ablation</description>
    <arm_group_label>ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digaoxin,amiodarone,Î² receptor antagonist, Calcium Antagonists</intervention_name>
    <arm_group_label>Antiarrythmic Drugs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1 Patients with symptomatic AF recorded by ECG or Holter 2 Age:18-75 years 3 Patients
             who are willing to enroll in the trial

        Exclusion Criteria:

          -  1 Patients accompanied hyperthyroidism 2 Patients with sever liver or renal
             dysfunction 3 Patients with sever cardiac dysfunction 4 Patients had previous
             radiofrequency catheter ablation in the LA or Maze surgical procedure 5 Patients with
             emboli in atrium 6 Pregnant woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cong xin Huang, doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Renmin Hospital of Wuhan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cong xin Huang, doctor</last_name>
    <phone>13907131546</phone>
    <email>huangcongxin@yahoo.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Renmin Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cong xin Huang, doctor</last_name>
      <phone>13907131546</phone>
      <email>huangcongxin@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>cong xin Huang, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2011</study_first_submitted>
  <study_first_submitted_qc>April 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2011</study_first_posted>
  <last_update_submitted>April 21, 2011</last_update_submitted>
  <last_update_submitted_qc>April 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>Cong-xin Huang,doctor</name_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
    <mesh_term>Calcium Channel Blockers</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

